The antimicrobial activity of ceftobiprole against Methicillin-resistant Staphylococcus aureus and multi-drug resistant Pseudomonas aeruginosa: A large tertiary care university hospital experience in Riyadh, Saudi Arabia

Lamees A. Altamimi; Leen A. Altamimi; Ali M. Somily

doi:10.15537/smj.2022.43.1.20210587

References

1.↵
1. Stein RA,
2. Goetz RM,
3. Ganea GM.
Ceftobiprole: a new beta-lactam antibiotic. Int J Clin Pract 2009; 63: 930–943.
OpenUrl CrossRef PubMed Web of Science
2.↵
1. Pang Z,
2. Raudonis R,
3. Glick BR,
4. Lin TJ,
5. Cheng Z.
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 2019; 37: 177–192.
OpenUrl CrossRef PubMed
3.↵
1. Zowawi HM.
Antimicrobial resistance in Saudi Arabia. An urgent call for an immediate action. Saudi Med J 2016; 37: 935–940.
OpenUrl Abstract/FREE Full Text
4.↵
1. Holmes NE,
2. Tong SY,
3. Davis JS,
4. van Hal SJ.
Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med 2015; 36: 17–30.
OpenUrl CrossRef PubMed
5.↵
1. Purrello SM,
2. Garau J,
3. Giamarellos E,
4. Mazzei T,
5. Pea F,
6. Soriano A, et al.
Methicillin-resistant Staphylococcus aureus infections: a review of the currently available treatment options. J Glob Antimicrob Resist 2016; 7: 178–186.
OpenUrl
6.↵
1. Bruniera FR,
2. Ferreira FM,
3. Saviolli LR,
4. Bacci MR,
5. Feder D,
6. da Luz Gonçalves Pedreira M, et al.
The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci 2015; 19: 694–700.
OpenUrl PubMed
7.↵
1. Li B,
2. Webster TJ.
Bacteria antibiotic resistance: new challenges and opportunities for implant-associated orthopedic infections. J Orthop Res 2018; 36: 22–32.
OpenUrl CrossRef
8.↵
1. Mpenge MA,
2. MacGowan AP.
Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia. Ther Clin Risk Manag 2015; 11: 565–579.
OpenUrl CrossRef PubMed
9.↵
1. Flamm RK,
2. Duncan LR,
3. Hamed KA,
4. Smart JI,
5. Mendes RE,
6. Pfaller MA.
Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018. Antimicrob Agents Chemother 2020; 64: e02566–e02519.
OpenUrl
10.↵
1. Pfaller MA,
2. Flamm RK,
3. Mendes RE,
4. Streit JM,
5. Smart JI,
6. Hamed KA, et al.
Ceftobiprole activity against Gram-positive and -negative pathogens collected from the United States in 2006 and 2016. Antimicrob Agents Chemother 2018; 63: e01566–e01518.
OpenUrl CrossRef
11.↵
1. Pfaller MA,
2. Flamm RK,
3. Duncan LR,
4. Streit JM,
5. Castanheira M,
6. Sader HS.
Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). Diagn Microbiol Infect Dis 2018; 91: 77–84.
OpenUrl
12.↵
1. Giacobbe DR,
2. De Rosa FG,
3. Del Bono V,
4. Grossi PA,
5. Pea F,
6. Petrosillo N, et al.
Ceftobiprole: drug evaluation and place in therapy. Expert Rev Anti Infect Ther 2019; 17: 689–698.
OpenUrl CrossRef
13.↵
1. Hawser S,
2. Kothari N,
3. Karlowsky JA,
4. Wiktorowicz T,
5. Hamed K.
In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates. Diagn Microbiol Infect Dis 2020; 96: 114978.
OpenUrl
14.↵
1. Falcó V,
2. Burgos J,
3. Almirante B.
Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother 2018; 19: 1503–1509.
OpenUrl
15.↵
1. Antonelli A,
2. Giani T,
3. Coppi M,
4. Di Pilato V,
5. Arena F,
6. Colavecchio OL, et al.
Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates. J Antimicrob Chemother 2019; 74: 3453–3461.
OpenUrl
16.↵
1. Carnesecchi G,
2. Lobello R,
3. Liggieri L,
4. Palmero C,
5. Pescetto L,
6. Morelli P, et al.
In vitro activity of ceftaroline and ceftobiprole against methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin isolated in paediatric patients. J Chemother 2018; 30: 338–341.
OpenUrl
17.↵
1. Zhanel GG,
2. Lam A,
3. Schweizer F,
4. Thomson K,
5. Walkty A,
6. Rubinstein E, et al.
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008; 9: 245–254.
OpenUrl CrossRef PubMed Web of Science
18.↵
1. Bogdanovich T,
2. Ednie LM,
3. Shapiro S,
4. Appelbaum PC.
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210–4219.
OpenUrl Abstract/FREE Full Text
19.↵
1. David MZ,
2. Dryden M,
3. Gottlieb T,
4. Tattevin P,
5. Gould IM.
Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new. Int J Antimicrob Agents 2017; 50: 303–307.
OpenUrl
20.↵
1. Magiorakos AP,
2. Srinivasan A,
3. Carey RB,
4. Carmeli Y,
5. Falagas ME,
6. Giske CG, et al.
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268–281.
OpenUrl CrossRef PubMed
21.↵
CLSI. Performance standards for antimicrobial susceptibility testing (28th ed.) CLSI supplement M100. Clinical and Laboratory Standards Institute; [Updated 2018; 2020 July 19]. Available from: https://clsi.org/media/1930/m100ed28_sample.pdf
22.↵
EUCAST. Ceftobiprole: Rationale for the clinical breakpoints (version 1.0). [Updated 2016; 2018 May 16]. Available from: https://eucast.org/
23.↵
1. Grau S.
Safety and tolerability of ceftobiprole. Rev Esp Quimioter 2019; 32: 34–36.
OpenUrl
24.↵
1. Mahmoud E,
2. Al Mansour S,
3. Bosaeed M,
4. Alharbi A,
5. Alsaedy A,
6. Aljohani S, et al.
Ceftobiprole for treatment of MRSA blood stream infection: a case series. Infect Drug Resist 2020; 13: 2667–2672.
OpenUrl
25.↵
1. Morroni G,
2. Brenciani A,
3. Brescini L,
4. Fioriti S,
5. Simoni S,
6. Pocognoli A, et al.
High rate of ceftobiprole resistance among clinical Methicillin-resistant Staphylococcus aureus isolates from a hospital in Central Italy. Antimicrob Agents Chemother 2018; 62: e01663–e01618.
OpenUrl
26.↵
1. Farrell DJ,
2. Flamm RK,
3. Sader HS,
4. Jones RN.
Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005-2010. Antimicrob Agents Chemother 2014; 58: 3882–3888.
OpenUrl Abstract/FREE Full Text
27.↵
1. Horcajada JP,
2. Montero M,
3. Oliver A,
4. Sorlí L,
5. Luque S,
6. Gómez-Zorrilla S, et al.
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 2019; 32: e00031–e00019.
OpenUrl
28.↵
1. Rossolini GM,
2. Dryden MS,
3. Kozlov RS,
4. Quintana A,
5. Flamm RK,
6. Läuffer JM, et al.
Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. J Antimicrob Chemother 2011; 66: 151–159.
OpenUrl CrossRef PubMed
29.↵
1. Bilman F,
2. Turhanoğlu M.
Antimicrobial activity of ceftaroline and ceftobiprole tested against MRSA isolates from Turkey in 2016. IOSR-JPBS 2016; 11: 52–56.
OpenUrl

In this issue

Download PDF

Email Article

Citation Tools

Bookmark this article

Cited By...

No citing articles found.

Google Scholar

More in this TOC Section

Show more Original Articles

Keywords

[1] 1.↵
Stein RA,
Goetz RM,
Ganea GM.
Ceftobiprole: a new beta-lactam antibiotic. Int J Clin Pract 2009; 63: 930–943.
OpenUrl CrossRef PubMed Web of Science

[2] Stein RA,

[3] Goetz RM,

[4] Ganea GM.

[5] 2.↵
Pang Z,
Raudonis R,
Glick BR,
Lin TJ,
Cheng Z.
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 2019; 37: 177–192.
OpenUrl CrossRef PubMed

[6] Pang Z,

[7] Raudonis R,

[8] Glick BR,

[9] Lin TJ,

[10] Cheng Z.

[11] 3.↵
Zowawi HM.
Antimicrobial resistance in Saudi Arabia. An urgent call for an immediate action. Saudi Med J 2016; 37: 935–940.
OpenUrl Abstract/FREE Full Text

[12] Zowawi HM.

[13] 4.↵
Holmes NE,
Tong SY,
Davis JS,
van Hal SJ.
Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med 2015; 36: 17–30.
OpenUrl CrossRef PubMed

[14] Holmes NE,

[15] Tong SY,

[16] Davis JS,

[17] van Hal SJ.

[18] 5.↵
Purrello SM,
Garau J,
Giamarellos E,
Mazzei T,
Pea F,
Soriano A, et al.
Methicillin-resistant Staphylococcus aureus infections: a review of the currently available treatment options. J Glob Antimicrob Resist 2016; 7: 178–186.
OpenUrl

[19] Purrello SM,

[20] Garau J,

[21] Giamarellos E,

[22] Mazzei T,

[23] Pea F,

[24] Soriano A, et al.

[25] 6.↵
Bruniera FR,
Ferreira FM,
Saviolli LR,
Bacci MR,
Feder D,
da Luz Gonçalves Pedreira M, et al.
The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci 2015; 19: 694–700.
OpenUrl PubMed

[26] Bruniera FR,

[27] Ferreira FM,

[28] Saviolli LR,

[29] Bacci MR,

[30] Feder D,

[31] da Luz Gonçalves Pedreira M, et al.

[32] 7.↵
Li B,
Webster TJ.
Bacteria antibiotic resistance: new challenges and opportunities for implant-associated orthopedic infections. J Orthop Res 2018; 36: 22–32.
OpenUrl CrossRef

[33] Li B,

[34] Webster TJ.

[35] 8.↵
Mpenge MA,
MacGowan AP.
Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia. Ther Clin Risk Manag 2015; 11: 565–579.
OpenUrl CrossRef PubMed

[36] Mpenge MA,

[37] MacGowan AP.

[38] 9.↵
Flamm RK,
Duncan LR,
Hamed KA,
Smart JI,
Mendes RE,
Pfaller MA.
Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018. Antimicrob Agents Chemother 2020; 64: e02566–e02519.
OpenUrl

[39] Flamm RK,

[40] Duncan LR,

[41] Hamed KA,

[42] Smart JI,

[43] Mendes RE,

[44] Pfaller MA.

[45] 10.↵
Pfaller MA,
Flamm RK,
Mendes RE,
Streit JM,
Smart JI,
Hamed KA, et al.
Ceftobiprole activity against Gram-positive and -negative pathogens collected from the United States in 2006 and 2016. Antimicrob Agents Chemother 2018; 63: e01566–e01518.
OpenUrl CrossRef

[46] Pfaller MA,

[47] Flamm RK,

[48] Mendes RE,

[49] Streit JM,

[50] Smart JI,

[51] Hamed KA, et al.

[52] 11.↵
Pfaller MA,
Flamm RK,
Duncan LR,
Streit JM,
Castanheira M,
Sader HS.
Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). Diagn Microbiol Infect Dis 2018; 91: 77–84.
OpenUrl

[53] Pfaller MA,

[54] Flamm RK,

[55] Duncan LR,

[56] Streit JM,

[57] Castanheira M,

[58] Sader HS.

[59] 12.↵
Giacobbe DR,
De Rosa FG,
Del Bono V,
Grossi PA,
Pea F,
Petrosillo N, et al.
Ceftobiprole: drug evaluation and place in therapy. Expert Rev Anti Infect Ther 2019; 17: 689–698.
OpenUrl CrossRef

[60] Giacobbe DR,

[61] De Rosa FG,

[62] Del Bono V,

[63] Grossi PA,

[64] Pea F,

[65] Petrosillo N, et al.

[66] 13.↵
Hawser S,
Kothari N,
Karlowsky JA,
Wiktorowicz T,
Hamed K.
In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates. Diagn Microbiol Infect Dis 2020; 96: 114978.
OpenUrl

[67] Hawser S,

[68] Kothari N,

[69] Karlowsky JA,

[70] Wiktorowicz T,

[71] Hamed K.

[72] 14.↵
Falcó V,
Burgos J,
Almirante B.
Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother 2018; 19: 1503–1509.
OpenUrl

[73] Falcó V,

[74] Burgos J,

[75] Almirante B.

[76] 15.↵
Antonelli A,
Giani T,
Coppi M,
Di Pilato V,
Arena F,
Colavecchio OL, et al.
Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates. J Antimicrob Chemother 2019; 74: 3453–3461.
OpenUrl

[77] Antonelli A,

[78] Giani T,

[79] Coppi M,

[80] Di Pilato V,

[81] Arena F,

[82] Colavecchio OL, et al.

[83] 16.↵
Carnesecchi G,
Lobello R,
Liggieri L,
Palmero C,
Pescetto L,
Morelli P, et al.
In vitro activity of ceftaroline and ceftobiprole against methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin isolated in paediatric patients. J Chemother 2018; 30: 338–341.
OpenUrl

[84] Carnesecchi G,

[85] Lobello R,

[86] Liggieri L,

[87] Palmero C,

[88] Pescetto L,

[89] Morelli P, et al.

[90] 17.↵
Zhanel GG,
Lam A,
Schweizer F,
Thomson K,
Walkty A,
Rubinstein E, et al.
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008; 9: 245–254.
OpenUrl CrossRef PubMed Web of Science

[91] Zhanel GG,

[92] Lam A,

[93] Schweizer F,

[94] Thomson K,

[95] Walkty A,

[96] Rubinstein E, et al.

[97] 18.↵
Bogdanovich T,
Ednie LM,
Shapiro S,
Appelbaum PC.
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210–4219.
OpenUrl Abstract/FREE Full Text

[98] Bogdanovich T,

[99] Ednie LM,

[100] Shapiro S,

[101] Appelbaum PC.

[102] 19.↵
David MZ,
Dryden M,
Gottlieb T,
Tattevin P,
Gould IM.
Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new. Int J Antimicrob Agents 2017; 50: 303–307.
OpenUrl

[103] David MZ,

[104] Dryden M,

[105] Gottlieb T,

[106] Tattevin P,

[107] Gould IM.

[108] 20.↵
Magiorakos AP,
Srinivasan A,
Carey RB,
Carmeli Y,
Falagas ME,
Giske CG, et al.
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268–281.
OpenUrl CrossRef PubMed

[109] Magiorakos AP,

[110] Srinivasan A,

[111] Carey RB,

[112] Carmeli Y,

[113] Falagas ME,

[114] Giske CG, et al.

[115] 21.↵
CLSI. Performance standards for antimicrobial susceptibility testing (28th ed.) CLSI supplement M100. Clinical and Laboratory Standards Institute; [Updated 2018; 2020 July 19]. Available from: https://clsi.org/media/1930/m100ed28_sample.pdf

[116] 22.↵
EUCAST. Ceftobiprole: Rationale for the clinical breakpoints (version 1.0). [Updated 2016; 2018 May 16]. Available from: https://eucast.org/

[117] 23.↵
Grau S.
Safety and tolerability of ceftobiprole. Rev Esp Quimioter 2019; 32: 34–36.
OpenUrl

[118] Grau S.

[119] 24.↵
Mahmoud E,
Al Mansour S,
Bosaeed M,
Alharbi A,
Alsaedy A,
Aljohani S, et al.
Ceftobiprole for treatment of MRSA blood stream infection: a case series. Infect Drug Resist 2020; 13: 2667–2672.
OpenUrl

[120] Mahmoud E,

[121] Al Mansour S,

[122] Bosaeed M,

[123] Alharbi A,

[124] Alsaedy A,

[125] Aljohani S, et al.

[126] 25.↵
Morroni G,
Brenciani A,
Brescini L,
Fioriti S,
Simoni S,
Pocognoli A, et al.
High rate of ceftobiprole resistance among clinical Methicillin-resistant Staphylococcus aureus isolates from a hospital in Central Italy. Antimicrob Agents Chemother 2018; 62: e01663–e01618.
OpenUrl

[127] Morroni G,

[128] Brenciani A,

[129] Brescini L,

[130] Fioriti S,

[131] Simoni S,

[132] Pocognoli A, et al.

[133] 26.↵
Farrell DJ,
Flamm RK,
Sader HS,
Jones RN.
Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005-2010. Antimicrob Agents Chemother 2014; 58: 3882–3888.
OpenUrl Abstract/FREE Full Text

[134] Farrell DJ,

[135] Flamm RK,

[136] Sader HS,

[137] Jones RN.

[138] 27.↵
Horcajada JP,
Montero M,
Oliver A,
Sorlí L,
Luque S,
Gómez-Zorrilla S, et al.
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 2019; 32: e00031–e00019.
OpenUrl

[139] Horcajada JP,

[140] Montero M,

[141] Oliver A,

[142] Sorlí L,

[143] Luque S,

[144] Gómez-Zorrilla S, et al.

[145] 28.↵
Rossolini GM,
Dryden MS,
Kozlov RS,
Quintana A,
Flamm RK,
Läuffer JM, et al.
Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. J Antimicrob Chemother 2011; 66: 151–159.
OpenUrl CrossRef PubMed

[146] Rossolini GM,

[147] Dryden MS,

[148] Kozlov RS,

[149] Quintana A,

[150] Flamm RK,

[151] Läuffer JM, et al.

[152] 29.↵
Bilman F,
Turhanoğlu M.
Antimicrobial activity of ceftaroline and ceftobiprole tested against MRSA isolates from Turkey in 2016. IOSR-JPBS 2016; 11: 52–56.
OpenUrl

[153] Bilman F,

[154] Turhanoğlu M.

Main menu

User menu

Search

The antimicrobial activity of ceftobiprole against Methicillin-resistant Staphylococcus aureus and multi-drug resistant Pseudomonas aeruginosa

A large tertiary care university hospital experience in Riyadh, Saudi Arabia

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS

Main menu

User menu

Search

The antimicrobial activity of ceftobiprole against Methicillin-resistant Staphylococcus aureus and multi-drug resistant Pseudomonas aeruginosa

A large tertiary care university hospital experience in Riyadh, Saudi Arabia

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS